A new medical cannabis service has been launched by Boots Online Doctor, the retailer has announced.

‘SureLeaf’ is a ‘specialist, doctor-led’ service for people living with eligible chronic pain conditions, insomnia or generalised anxiety disorder, and offers patients ‘another treatment option where conventional treatments have not provided adequate symptom relief’. The service, the first from a UK high street pharmacy, will be continually supported by specialist clinical assessment and care, Boots states.
Patients aged 25 or above with an eligible condition can complete an online assessment, which is then evaluated by a clinical team – eligible chronic pain conditions include chronic primary and neuropathic pain, sciatica, chronic back or neck pain, osteoarthritis, rheumatoid arthritis, chronic migraine, endometriosis-related pelvic pain and others. To qualify, patients must have already tried conventional treatments ‘without achieving adequate symptom relief’. Suitable patients can then have a video consultation with a GMC-registered consultant, with any prescription reviewed by a multidisciplinary team including a second independent consultant.
The service will combine multidisciplinary oversight and patient monitoring throughout the course of treatment, Boots says, with a review after 28 days and further reviews at least every three months. Questionnaires will also be used to assess areas like pain levels, anxiety, sleep, mood and quality of life, while a collaborative research programme with the University of Nottingham will examine patient outcomes and experiences, as well as prescribing practice, to ‘build on the existing real-world evidence and understanding of medical cannabis in chronic pain management’.
A review of more than 50 randomised control trials by researchers at the universities of Sydney, Melbourne, Brisbane and Bath published earlier this year concluded that there was no evidence that medicinal cannabis was an effective treatment for some common mental health conditions like depression, anxiety or PTSD, although they said more research was needed.
‘Medical cannabis is not appropriate for everyone and prescribing decisions need to be made carefully on an individual patient basis,’ said medical director at Boots Online Doctor, Dr David Gwynne. ‘SureLeaf has therefore been designed with strong clinical safeguards and specialist oversight at every stage, so treatment is only considered for patients where it is clinically appropriate. Our priority is to ensure patients receive responsible, clinically led care, from their initial specialist assessment through to ongoing monitoring and review once treatment begins.’
Full details here

